Current perspectives in the surgery of multiple endocrine neoplasias

Australian and New Zealand Journal of Surgery

Volumn 69, Issue 2, 1999, Pages 106-116

  Prove, Charles A G ^a   Nguyen, Hieu H ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Gastrinoma; Hyperparathyroidism; Insulinoma; Medullary cancer of thyroid; Multiple endocrine neoplasia; Pheochromocytoma

Indexed keywords

AUTOPSY; CANCER SURVIVAL; GASTRINOMA; GENE MUTATION; GENETIC LINKAGE; GLUCAGONOMA; HUMAN; HYPERPARATHYROIDISM; HYPOPHYSIS TUMOR; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS TUMOR; PHEOCHROMOCYTOMA; PROGNOSIS; REVIEW; THYROID CANCER; TREATMENT OUTCOME; VIPOMA;

ADRENAL GLAND NEOPLASMS; CARCINOMA, MEDULLARY; GASTRINOMA; GENETIC SCREENING; HUMANS; HYPERPARATHYROIDISM; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA; PANCREATIC NEOPLASMS; PHEOCHROMOCYTOMA; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0032915398     PISSN: 00048682     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1622.1999.01513.x     Document Type: Review

References (124)

1. Shepperd J. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized? Arch. Surg. 1991;126:935-52.
2. Casanova S, Rosenberg-Bourgin M, Farkas D et al. Pheochromocytoma in multiple endocrine neoplasia type 2a: survey of 100 cases. Clin. Emlocrinol. 1993; 38: 531-7.
3. Zollinger RM, Ellison EC, O'Dorsio TM, Sparrs J. Thirty years experience with gastrinoma. World J. Surg. 1984; 8: 427-35.
4. Schuffenecker I, Billaud M, Calender A et al. RET proto-oncogene mutations in French MEN 2a and FMTC families. Human Mol. Genet. 1994; 3: 1939-43.
5. Mulligan LM, Kvvok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a. Nature 1993; 363: 458-60.
6. Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2a and FMTC. Nature Genet. 1994; 6: 70-4.
7. Donis-Keller H, Dou S, Chi D et al. Mutations in the RETproto-oncogene are associated with MEN 2A and FMTC. Human Mol. Genet. 1993; 2: 851-6.
8. Chandrasekharappa SC, Guru SC, Manickham P et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 1997; 276: 404-7.
9. Howe JR, Norton JA, Wells SA. The prevalence of pheochromocytoma and hyperparathyroidism in multiple neoplasia type 2A: Results of long-term follow-up. Surgery 1993; 114: 1070-7.
10. Kraimps JL, Denizot A, Carnaille B et al. Primary hyperparathyroidism in multiple endocrine neoplasia type Ha: Retrospective French multicentric study. World J. Surg. 1996; 20: 808-13.
11. Snow KJ, Boyd AE. Management of individual tumor syndromes, medullary thyroid carcinoma and hyperparathyroidism. EndocrinoLMetabol. Clin. North Am. 1994; 23-157.
12. Norton JA, Comellius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism and Zollinger-Ellison syndrome (ZES) in the setting of MEN: A prospective study. Surgery 1987; 102:958-66.
13. O'Riordain DS, O'Brien T, Grant CS, Weaver A, Gharib H, Van Heerden JA. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1 and 2. Surgery 1993; 114: 1031-9.
14. Decker RA, Peacock ML, Borst MT, Sweet DD, Thompson NW. Progress in genetic screening of multiple endocrine neoplasia type 2A: Is calcitonin testing obsolete? Surgery 1995; 118: 257-64.
15. Telander RL, Zimmerman D, Sizemore GW, Van Heerden JA, Grant CS. Medullary thyroid carcinoma: Results of early detection and surgery. Arch. Surg. 1989; 124: 841-3.
16. Murat A, Modigliani E, Conte-Devolx B étal. Résultats de la prise en charge thérapeutique précoce des sujets prédisposés géné tiquement au cancer médullaire de la thyroïde (CMT). Ann. Endocr. (Paris) 1997; 2: 25-122.
17. Wells Jr SA, Chi DD, Toshima K et al. Predictive DNA Testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann. Surg. 1994; 220: 237-50.
18. Pacini F, Romei C, Miccoli P et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 1995; 118: 1031-5.
19. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Surgery 1995; 118: 1099-104.
20. Roher HD, Simon D, Goretzki PE, Hoppner W, Lederbogen S, Seppel T. Die prophylaktische Radikaloperation des C-Zell Carcinoms beim MEN Syndrom auf der Grundlage des genetischen Screening. Chirurg. 1995; 66: 1196-202.
21. Decker RA, Geiger JD, Cox CE, Mackovjak M, Sarkar M, Peacock ML. Prophylactic surgery for multiple endocrine neoplasia type A after genetic diagnosis: Is parathyroid transplantation indicated? World J. Surg. 1996; 20: 814-21.
22. Dralle H, Scheumann GFW, Proye C et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: a retrospective, European, multicentre study. J. Int. Med. 1995; 238:357-61.
23. Gimm O, Holzhausen HJ, Dralle H. Results of surgery in children and adolescents with MEN 2a syndrome. Ada Cliir. Austr. 1996; 28 (Suppl.): 113-28. '
24. Graham SM, Genel M, Touloukian RJ, Barwick KW, Gertner JM, Torony C. Provocative testing for occult medullary carcinoma of the thyroid: findings in seven children with multiple endocrine neoplasia type Ha. J. Pediatr. Surg. 1987; 22: 501-3.
25. Frank-Raue K, Buhr H, Senninger N, Hoppner W, Raue F. Prophylactic thyroidectomy in children with germline mutation in the RET proto-oncogene. Ada Cliir. Austr. 1996; 28 (Suppl.): 128-31.
26. Raue F, Frank-Raue K. Biochemical parameters in diagnosis and follow-up of patients with multiple endocrine neoplasia type 2. Acta Chir. Austr. 1997; 29: 9-11.
27. Franz C, Wells Jr SA. Prophylactic thyroidectomy in MEN 2 gene carriers. Acta Cliir. Austr. 1997; 29: 12-14.
28. Glowniak JV, Shapiro B, Sisson JC, Thompson NW et al. Familial extra-adrenal pheochromocytoma: A new syndrome. Arch. Int. Med. 1985; 145: 257-61.
29. Eng C, Mulligan LM, Smith DP et al. Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin. Endocrinol. 1995; 43: 123-7.
30. Eng C. Genetic screening in hereditary medullary thyroid carcinoma. Ada Chir. Austr. 1997; 29: 5-8.
31. Proye C. Les phéochromocytomes. In: Chapuis Y, Peix JL (eds). Chirurgie Des Glandes Surrénales. Paris: Arnette, 1994; 89-114.
32. Proye C, Vix M, Jansson S, Tissell LE, Dralle H, Hiller W. The pheochromocytoma: A benign intraadrenal, hypertensive, sporadic, unilateral tumor. Does it exist? World J. Sitrg. 1994; 18: 467-72.
33. Proye C. Modern trends in the management of pheochromocytomas and abdominal paracangliomas. Endocrine Surg. 1996; 13: 109-23.
34. Marks AD, Channick BJ. Extraadrenal pheochromocytoma and medullary thyroid carcinoma with pheochromocytoma. Arch. IntMed. 1974; 134: 1106-9.
35. Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte-Houcke M. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out 100 patients operated from 1971 to 1991. J. Endocrinol. Investig. 1992; 15: 651-62.
36. Mornex R, Peyrin L, Pagliari R, Cottet-Emard JM. Measurement of plasma methoxyamines for the diagnosis of pheochromocytoma. Harm. Res. 1996; 36: 220-6.
37. Paineau J, Blanloeil Y, Legrand D et al. Hypoglycémie postopératoire après ablation d'un phéochromocytome: Une observation. Presse Med. 1988; 17:475-8.
38. Lairmore TC, Ball DW, Baylin SB, Wells Jr SA. Management of phechromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann. Surg. 1993; 217: 595-603.
39. Lee JE, Curley SA, Gagel RF, Evans DB, Hickey RC. Corticalsparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120: 1064-71.
40. Pichlmayr R, Weimann A, Oldhafer KF et al. Role of liver transplantation in the treatment of unresectable liver cancer. World J. Surg. 1995; 19: 807-13.
41. Tavernier B, Haulier MB, Sperandio M, Proye C, Scherpereel Ph. Anesthésie-réanimation pour chirurgie du phéochromocytome. Ann. Chir. 1997; 51: 352-60.
42. Mihm FG, Sandhu JS, Brown MD, Rosenthal MI. Short-acting beta-adrenergic blockade as initial drug therapy in pheochromocytoma. Crit. Care Med. 1990; 18: 673-4.
43. Ryan T, Timoney A, Cunningham J. Use of transoesophageal echocardiography to manage beta-adrenoreceptor block and assess left ventricular function in a patient with pheochromocytoma. Br. J. Anaesth. 1993; 70: 101-3.
44. Zakowski M, Kaufman B, Berguson P, Tissot M, Yarmush L, Turndorf H. Esmolol use during resection of pheochromocytoma: Report of three cases. Anesthesiology 1989; 70: 875-7.
45. Pattou F, Combemale FP, Poirette JF et al. Questionability of the benefits of routine laparotomy as the surgical approach for pheochromocytomas and abdominal paragangliomas. Surgery 1996; 120: 1006-12.
46. Fernandez-Cruz L, Taura P, Saenz A, Bennaroch G, Sabater L. Laparoscopic approach of pheochromocytoma: Hemodynamic changes and catecholamine secretion. World J. Surg. 1996; 20: 762-8.
47. Gagner M, Lacroix A, Boite E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma. W. Engl. J. Med. 1992; 327: 1033.
48. Gagner M, Lacroix A, Prinz RA et al. Early experience with laparoscopic approach for adrenalectomy. Surgery 1993; 114: 1120-5.
49. Hamoir E, Meurisse M, Joris J. L'exérèse coelioscopique des phéochromocytomes. Etude détaillée des modifications hémodynamiques per-opératoires. Lyon Chir. 1994; 91: 515-22.
50. Freier DT, Thompson NW. Pheochromocytoma and pregnancy: The epitome of high risk. Surgery 1993; 114:'l 148-52.
51. Boissel P, Proye C. Les tumeurs endocrines du pancréas. In: Rapport Au 87th Congrès De Liafc. Paris: Masson, 1985.
52. Proye C. Tumeurs endocrines du pancréas. In: Editions Techniques - Encyclopédie Médico-Chirurgicale. Paris: Encyclopédie Médico-Chirurgicale, 1995.
53. Grama D, Skogseid B, Wilander E et al. Pancreatic tumors in multiple endocrine neoplasia type 1: Clinical presentation and surgical treatment. World J. Surg. 1992; 16: 611-19.
54. Grama D, Eriksson B, Martensson H et al. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J. Sitrg. 1992; 16: 632-9.
55. Goudswaard WB, Houthoff HJ, Koudstaal J, Zwierstra RP. j Nesidioblastosis and endocrine hyperplasia of the pancreas: A secondary phenomenon. Human Pathol. 1986; 17: 46-54.
56. Larsson LI. Two distinct types of islet abnormalities associated with endocrine pancreatic tumours. Virchows Arch. A Pathol. Pathol. Anat. 1977; 376: 209-19.
57. Thompson NW, Lloyd RV, Nishiyama RH et al. MEN 1 pancreas: A histological and immunohistochemical study. World J. Surg. 1984; 8: 561-74.
58. Rösch T, Lightdale CJ, Botet JF et al. Localization of pancreatic endocrine tumors by endoscopie ultrasonography. N. Engl. J. Med. 1992; 326: 1721-6.
59. Ruszniewski P, Amouyal P, Amouyal G et al. Localization of gastrinomas by endoscopie unltrasonography in patients with the Zollinger-Ellison syndrome. Surgery 1995; 117: 629-35.
60. Cadiot G, De Kerviler E, Lebtahi R, Le Guludec D, Mignon M. Chez quels malades atteints d'un syndrome de Zollinger-Ellison (SZE), la scintigraphie des récepteurs de la somatostatine (SRS) ' est-elle utile? G.C.B. 1994; 18: 843-7.
61. Cadiot G, Lebtahi R, Sarda L et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996; 111: 845-54.
62. Krenning EP, Bakker VH, Breeman WAP et al. Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989; 1: 242.
63. Doppman JL, Miller DL, Chang R, Shawker TH, Gorden P, Norton JA. Insulinomas: Localization with selective intra-arterial injection of calcium. Radiology 1991; 178: 237-41.
64. Doppman JL, Miller DL, Chang R, Gorden P, Eastman RC, Norton JA. Intraarterial calcium stimulation test for detection of insulinomas. World J. Surg. 1993; 17: 439-43.
65. Doppman JL, Chang RC, Fraker DL, Norton JA, Alexander HJ, Miller DL. Localization of insulinomas to regions of the pancreas by intraarterial stimulation with calcium. Ann. Int. Med. 1995; 123: 269-73.
66. Imamura M, Takahashi K. Use of selective arterial secretin injection test to guide surgery in patients with Zollinger-Ellison syndrome. World J. Surg. 1993; 17: 433-8.
67. Demeure MJ, Klonoff DC, Karam JH, Duh QY, Clark OH. Insulinomas associafed with MEN type I: The need for a different surgical approach. Surgery 1991; 110: 998-1005.
68. O'Riordain DS, O'Brien T, Van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J. Surg. 1994; 18: 488-94.
69. Van Boxsom P, Peix JL, Cougard P et al. Les insulinomes pancréatiques dans la néoplasie endocrinienne multiple de type I. Rev. Franc. End. Clin. 1995; 36: 105-18 (in French).
70. Me Farlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type I. Surgery 1995; 118: 973-80.
71. Papachristou DN, Fortner J. Pancreatic fistula complicating pancreatectomy for malignant disease. Br. J. Surg. 1981; 63: 238-40.
72. Kisker O, Spies T, Bastian D, Bartsch D, Geks J, Rothmund M. Diagnosis and therapy of asymptomatic gastrinomas in MEN 1 patients. Acta Cliir. Austr. 1996; 128: 18-9.
73. Melvin WS, Johnson JA, Sparks J, Innés JT, Ellison EC. Long-
74. term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 1993; 114: 1183-8.
75. Imamura M, Kanda M, Takahashi K et al. Clinicopathological characteristics of duodenal microgastrinomas. World J. Surg. 1992; 16: 703-10.
76. Pipeleers-Mdrichal M, Somers G, Willems G et al. Gastrinomas in the duodenum of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. N. Engl. J. Med. 1990; 322: 723-7.
77. Pipeleers-Marichal M, Donow C, Heitz PU, Klöppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type 1. World J. Surg. 1993; 17:481-8.
78. Thompson NW, Vinik AI, Eckhauser FE. Microgastrinomas of the duodenum. Ann. Surg. 1989; 209: 396-403.
79. Thompson NW, Pasieka J, Fukuuchi A. Duodenal gastrinomas, duodenotomy and duodenal exploration in the surgical management of Zollinger-Ellison syndrome. World J. Surg. 1993; 17: 455-62.
80. Thompson NW. Concepts in the operative management of MEN I pancreatic duodenal disease. Acta Cliir. Austr. 1996; 128: 19.
81. Goletti O, Chairugi M, Buccianti P et al. Resection of liver gastrinoma leading to persistent eugastrinemia. Eitr. J. Surg. 1992; 158: 55-7.
82. Cadiot G, Doukhan I, Vuagnat A et al. Facteurs de survie des malades atteints du syndrome de Zollinger-Ellison avec néoplasie endocrinienne multiple de type I (SZE + NEM 1): Etude multicentrique française chez 71 malades. Castro Eut. Clin. Biol. 1997; 21: A5.
83. Mignon M, Ratzui V. Medizinische Behandlung von sporadischen und familiären gastrinomen: eine aktuelle Strategie und ihre grenzen. Acta Cliir. Austr. 1992; 24: 76-81.
84. Mignon M, Ruszniewski P, Podevin P et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J. Surg. 1993; 17: 489-97.
85. Mignon M, Jensen RT. Endocrine Tumors of the Pancreas. Recent Advances in Research and Management. Basel: Switzerland, 1995.
86. McFarlane MP, Fraker DL, Alexander HR, Norton JA, Lubensky I, Jensen RT. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type I. Surgery 1995; 118: 973-80.
87. Norton JA, Jensen RT. Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome. World J. Surg. 1991; 15: 151-9.
88. Sheppard BC, Norton JA, Doppman JL, Maton PN, Gardner JD, Jensen RT. Management of islet cell tumors in patients with multiple endocrine neoplasia: A prospective study. Surgery 1989; 106: 1108-18.
89. Thompson NW, Bondeson AG, Bondeson L, Vinik A. The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery-1989; 106: 1081-6.
90. Thompson NW. Die Chirurgische Therapie des ZollingerEllison syndroms bei sporadischen und MEN I patienten. Acta Chir. Austr. 1992; 24: 82-7.
91. Skogseid B, Oberg K, Eriksson B et al. Asymptomatic pancreatic lesion in multiple endocrine neoplasia type 1: Resection for cancer prevention? Acta Chir. Austr. 1996; 128 (Suppl.): 18.
92. Skogseid B, Oberg K, Eriksson B el al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J. Surg. 1996; 20: 872-7.
93. Zeiger MR, Shawker TH, Norton JA. Use of intraoperative ultrasonography to localize islet cell tumors. World J. Surg. 1993; 17: 448-54.
94. Schirmer WJ, O'dorsio TM, Schirmer TP, Mojzisik CM, Hinkle GH, Martin EW. Intraoperative localization of neuroendocrine tumors with 125-I-TYR (3)-octreotide and a handheld gamma detecting probe. Surgery 1993; 114: 745-52.
95. Woltering EA, Barrie R, O'dorsio TM, O'dorsio MS, Nance R, Cook DM. Detection of occult gastrinomas utilizing 1251 labelled Lanreotide and intraoperative gamma detection. Surgery 1994; 116: 1139-47.
96. Frucht H, Norton JA, London JF el al. Detection of duodenal gastrinomas by operative endoscopie transillumination. Gastroenterology 1990; 99: 1622-7.
97. Delcore R, Friesen SR. Role of pancreaduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome. Surgery 1992; 112: 1016-23.
98. Gagner M, Pomp A, Herrera MF. Early experience with laparoscopic resection of islet cell tumors. Surgery 1996; 120: 1051.
99. Virgolini I, Raderer M, Kurtaran A et al. Vasointestinal peptid receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 1994; 331: 1116-21.
100. Thompson NW, Eckhauser FE, Vinik AJ, Lloyd RV, FiddianGreen RG, Strodel WE. Cystic neuroendocrine neoplasia of the pancreas and liver. Ann. Surg. 1984; 199: 158-64.
101. Ohneda A, Otsuki M, Fujiya H. A malignant insulinoma transformated into a glucagonoma syndrome. Diabetes 1979; 28: 962-9.
102. Wilson S. Zollinger-Ellison syndrome in children: A 25 year follow-up. Surgery 1991; 110: 696-703.
103. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990; 65: 1883-90.
104. Anthuber M, Jauch KW, Briegel J, Groh J, Schildberg FW. Results of liver transplantation for gastroenteropancreatic métastases". World J. Surg. 1996; 20: 73-6.
105. Perry LJ, Stuart K, Stokes KF, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994; 116: 1111-17.
106. Pichlmayr R, Weimann A, Oldhafer KF et al. Role of liver transplantation in the treatment of unresectable liver cancer. World J. Surg. 1995; 19: 807-13.
107. Me Entee GP, Nagorney DM, Kvole LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990; 108: 1091-6.
108. Tamasawa N, Terada A, Kodama J et al. Pheochromocytoma with multiple islet-cell carcinoma. Presse Med. 1994; 23: 32-4.
109. Huang SM, Duh QY, Shaver J, Siperstein AE, Kraimps JL, Clark OH. Familial hyperparathyroidism without multiple endocrine neoplasia. World J. Surg. 1997; 21: 22-9.
110. Jackson CE, Norum RA, Boyd SB et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990:108: 1006-13.
111. Richard S, Beigelman C, Duclos JM et al. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease. Surgery 1994; 116: 1076-81.
112. Huffman RW, Gardner DW, Mitchell FL. Intrathoracic and multiple abdominal pheochromocytomas in Von-Hippel-Lindau disease. Arch. Int. Med. 1982; 142: 1962-4.
113. Boubaddi NE, Imbert Y, Tissot B et al. Insulinome sécrétant et sclérose tubéreuse de Bourneville. Gcb. 1997; 21: 343.
114. Karasov RS, Sheps SG, Carney JA, Van Heerden JA, De Quatro V. Paragangliomatosis with numerous catecholamine producing tumors. Mayo Clinic Proc. 1982; 57: 590-5.
115. Gösset P, Carnaille B, Proye C, Lecomte-Houcke M. Adrenal and extra-adrenal pheochromocytomas: Contribution of histology immunochemistry and DNA flow cytometry in the diagnosis of malignancy. Eur. J. Surg. 1996; 162: 77.
116. 115.0'Riordain DS, Young WF, Grant CS, Carney A, Van Heerden JA. Clinical spectrum and outcome of extraadrenal pheochromocytoma. World J. Surg. 1996; 20: 916-22.
117. Mena J, Bowen JC, Hollier LH. Metachronous bilateral nonfunctional intercarotid paraganglioma (carotid body tumor) and functional retroperitoneal paraganglioma: report of a case and review of the literature. Surgery 1993; 114: 107-11.
118. Glowniak JV, Shapiro B, Sisson JC et al. Familial extraadrenal pheochromocytoma. A new syndrome. Arch. Int Med. 1985; 145: 257-61.
119. Lennard TWJ. Familial pheochromocytoma. A new syndrome? Br. J. Surg. 1995; 82: 1430.
120. Spring DB, Palubinskas AJ. Familial pheochromocytoma: a rare case of hydronephrosis and hydroureter in two generations. Dr. J. Radial. 1977; 50: 596-9.
121. Jeevanandam V, Oz MC, Shapiro B, Barr ML, Marboe C, Rose EA. Surgical management of cardiac pheochromocytoma. Aim. Surg. 1995; 221: 415-19.
122. Sweetser PM, Ohl DA, Thompson NW. Pheochromocytoma of the urinary bladder. Surgery 1991; 109: 677-81.
123. Aelbrecht S. Le Paragangliome de Lforgwie de Ziickerkandl. A Propos Dfun Cas Non Sécrétant Chez un Enfant de 10 Ans Et Revue De La Littérature. Lille: Thèse, 1996.
124. Proye C, Camaille B, Flament J et al. Intra-operative radionuclear I25l-labeled metaiodobenzylguanidine scanning of pheochromocytomas and métastases. Surgery 1991; 111: 634-9.